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Objectives This study sought to compare the procedural performance and the acute angiographic
result on side-branch ostium obtained using 2 different drug-eluting stents (DES) to treat patients
with bifurcated coronary lesions.
Background Drug-eluting stents are routinely used in percutaneous coronary interventions (PCI) of
bifurcated coronary lesions. Different DES types have major technical differences that may inﬂuence
the procedural and clinical performance in bifurcation PCI.
Methods Consecutive patients with bifurcated lesions undergoing DES implantation using a system-
atic provisional-stenting strategy were randomized to sirolimus-eluting stent (SES) or everolimus-
eluting stent (EES) before intervention. The procedural details for PCI were prospectively recorded to
assess the occurrence of any trouble in the side-branch (SB) management (primary end point). Post-
PCI angiographic result (primary end point: minimal lumen diameter at SB ostium) was evaluated
ofﬂine by 3-dimensional reconstruction and quantitative coronary analysis. Clinical outcome was
prospectively recorded up to 18 months to assess the occurrence of target bifurcation failure.
Results A total of 150 patients were enrolled in the study (29% diabetics, 17% unprotected left
main). The stent was successfully implanted according to randomization in all cases. Procedural per-
formance was not signiﬁcantly different between the 2 kinds of DES. Three-dimensional reconstruc-
tion and quantitative coronary analysis showed similar post-PCI results in the main vessel and better
results in the SB with EES than with SES (minimal lumen diameter at SB ostium: 1.94  0.72 mm vs.
.64  0.62 mm; p  0.013). At 18 months, target bifurcation failure occurred in 7 (9.0%) of SES-
treated patients versus 8 (10.7%) of EES patients (p  0.57).
Conclusions In patients with bifurcated lesions treated by provisional stenting technique, EES com-
pared with SES is associated with similar procedural performance and better 3-dimensional recon-
struction and quantitative coronary analysis result in the SB. Both DES are associated with low rates
of major adverse events and angiographic failure. (Sirolimus Versus Everolimus-Eluting Stent Ran-
domized Assessment in Bifurcated Lesions and Clinical Signiﬁcance of Residual Side-Branch Stenosis
[SEA-SIDE]; NCT00697372) (J Am Coll Cardiol Intv 2011;4:327–35) © 2011 by the American College
of Cardiology Foundation
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328Bifurcated lesions are challenging target lesions in percuta-
neous coronary interventions (PCI) that may specifically
benefit from drug-eluting stents (DES) (1). Since the
introduction of sirolimus-eluting stent (SES), various other
DES have been developed and tested in clinical practice in
different settings. Bifurcated lesions represent a particular
subset of lesions in which tubular stents are usually im-
planted by modifying their struts’ shape to take care of both
the main vessel (MV) and the side-branch (SB) using
various techniques (2). Accumulating clinical data suggest
that the best technique to treat most bifurcated lesions is the
“provisional” T-stenting approach, which is based on the
implantation of DES in the MV
followed, if deemed necessary,
by kissing balloon inflation and
side-branch (SB) stenting (2).
As different types of DES have
remarkable differences of metal-
lic stent platform, drug used,
and technology for drug-release,
the procedural and clinical per-
formance in bifurcation inter-
ventions may not be similar. In
keeping with this hypothesis, a
small randomized study (3) and
a recent large registry (4) sug-
gested that, when treating bifur-
cated lesions with first-generation
DES, SES might offer some
advantages over the paclitaxel-
eluting stent. Recently, a last-
generation everolimus-eluting
stent (EES) characterized by an
evolved stent platform (thin struts,
large side cells) has been shown to
provide promising results when
compared with a first-generation
(paclitaxel-eluting) DES (5) and
has entered the market.
Thus, we designed the present
single-center trial assessing the
procedural performance, the an-
giographic result, and the long-term clinical outcome ob-
tained by a first-generation DES (i.e., SES) compared with
a last-generation DES (i.e., EES) in unselected bifurcated
lesions.
Methods
Study registration and inclusion/exclusion criteria. The study
protocol design has been previously described and registered
in the ClinicalTrial.gov registry as the SEA-SIDE (Siroli-
mus Versus Everolimus-Eluting Stent Randomized Assess-
Abbreviations
and Acronyms
CK-MB  creatine kinase-
myocardial band
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
MACE  major adverse
coronary event(s)
MI  myocardial infarction
MLA  minimal lumen area
MLD  minimal lumen
diameter
MV  main vessel
PCI  percutaneous
coronary intervention
SB  side branch
SES  sirolimus-eluting
stent(s)
TAP-stenting  T-stenting
and small protrusion
technique
TBF  target bifurcation
failure
3DQCA  3-dimensional
reconstruction and
quantitative coronary
analysisment in Bifurcated Lesions and Clinical Significance ofResidual Side-Branch Stenosis) trial. The Ethical Commit-
tee of the Catholic University of the Sacred Heart approved
the study protocol.
From September 2007 to October 2008, consecutive
patients with documented coronary artery disease undergo-
ing PCI on a bifurcated lesion at our institution have been
screened to enter the study. To enter the study, patients had
to be 18 years of age; have no ascertained or suspected
contraindications to prolonged double antiplatelet therapy;
have no known hypersensitivity to sirolimus, everolimus,
cobalt, chromium, nickel, tungsten acrylic, and fluoropoly-
mers; and have no acute (within 48 h) ST-segment elevation
acute myocardial infarction.
Angiographic criteria to define bifurcated lesions eligible
for the study were:
1. Lesions: 50% located in a major bifurcation point
regardless of length, morphology, and angulation;
. TIMI (Thrombolysis In Myocardial Infarction) flow
grade: 2 on both MV and SB;
. MV visual diameter: 2.5 mm; and
. SB visual diameter: 2.0 mm.
Patients fulfilling these clinical and angiographic charac-
eristics and providing written informed consent entered the
rial and were randomized to the SES (Cypher Select,
ordis, Warren, New Jersey) or the EES (Xience V, Abbott
ascular, Santa Clara, California) stent (Fig. 1). To high-
light the major differences between the stent platforms of
EES and SES that may potentially influence the procedural
outcome during bifurcation interventions with provisional
approach, the pictures of stent design and bench testing of
MV stenting followed by kissing balloon inflation are
reported for both stents in Figure 2.
PCI. Percutaneous coronary interventions were performed
by radial or femoral approach according to the physician’s
preference. After confirmation of the presence of the criteria
for enrollment, patients were randomized to the type of
stent to be implanted (Fig. 1) according to a computer-
generated random series of numbers. Then, PCI has been
performed according to the previously reported “provisional
TAP-stenting strategy” (6). This means that all patients
were treated by MV stenting first under SB protection with
jailed guidewire technique, then SB rewiring was attempted
with a BMW Universal (Abbott Vascular), “workhorse
wire.” Furthermore, the kissing balloon technique was
performed if considered necessary by the operator (kissing
balloon being systematically attempted in cases of large
territories supplied by the SB or when SB exhibited flow
impairment after MV stenting). Then, if judged necessary
by the operator, a second stent was implanted in the SB
according to the T-stenting and small protrusion technique
(TAP-stenting) (7). Further details on the technical aspects
of the provisional TAP-stenting approach have been previ-
ously reported (6). In the case of occurrence of protocol
echniq
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329violations, patients were not excluded from the study and
operators had to justify the reason for the adoption of other
techniques.
The type of materials used and the sequence of their
usage was prospectively collected including: the occurrence
of SB flow impairment after MV stenting, the attempt to
rewire the SB after MV stenting, the type and number of
wires used for SB rewiring, the occurrence of failure to
rewire or to dilate the SB after MV stenting.
Procedural duration (from sheath insertion to sheath
removal or fixation with suture [in the case of decision to
delay sheath removal]), fluoroscopy time, and total radiation
exposure were prospectively recorded.
Procedural success was defined as TIMI flow grade 3 in
both MV and SB, as well as visual residual stenosis 20%
in MV.
Periprocedural medications. At the time of PCI, all patients
were on double antiplatelet therapy with aspirin (100 to 160
mg daily) and clopidogrel (300-mg loading dose on the day
before the PCI or 75 mg daily for more than 3 days before
the procedure). Procedural anticoagulation was achieved
with unfractionated heparin (70- to 100-U/kg intravenous
bolus with further dose adjustment to maintain an activated
clotting time of about 300 s). Use of glycoprotein IIb/IIIa
inhibitors was per operator discretion. After the procedure,
Figure 1. Study Flow Chart
The chart shows how patients were selected and randomized for this study. *S
everolimus-eluting stent(s); MV  main vessel; PCI  percutaneous coronary in
ment elevation myocardial infarction; TAP  T-stenting and small protrusion tall patients received double antiplatelet therapy with aspirin100 mg and clopidogrel 75 mg for 12 months with the
indication to continue aspirin indefinitely. According to our
internal guidelines on medical therapy of patients with
documented coronary artery disease, patients were pre-
scribed statins, beta-blockers, and angiotensin-converting
xt for detailed end point deﬁnitions. DES  drug-eluting stent(s); EES 
ntion; SB  side branch; SES  sirolimus-eluting stent(s); STEMI  ST-seg-
ue; TIMI  Thrombolysis In Myocardial Infarction; 3D  3-dimensional.
Figure 2. Aspect of SES and EES
Stent platform aspect (top) and ﬂuoroscopic appearance in bench testing
(main vessel stenting followed by kissing inﬂation [bottom]) of SES (A) andee te
terveEES (B). Abbreviations as in Figure 1.
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330enzyme inhibitors. Usage of nitrates was not recommended
after interventions.
Laboratory testing and follow-up. After PCI, all patients un-
derwent post-PCI electrocardiogram, and 6- and 24-h assessment
of troponin T and creatine kinase-myocardial band (CK-MB)
levels. Thereafter, further electrocardiogram and enzyme evalua-
tions were performed if clinically indicated.
After PCI, the in-hospital clinical course was carefully
monitored, whereas, after discharge, patients were
followed-up by hospital visit or by phone interview at 6, 9,
12, and 18 months. Follow-up coronary angiography has
not been planned in all patients. However, according to the
clinical practice of our center, follow-up angiography was
suggested to patients receiving double DES implantation at
the bifurcation level. Furthermore, all patients with symp-
toms’ recurrence and those with inducible ischemia at
4-month provocative tests have been recommended to
undergo angiographic evaluation.
Patients’ records and angiographic studies were carefully
reviewed for all suspect adverse events before adjudication.
The clinical events were defined as follows:
• Death: the cause of death has been ascertained by
reviewing the available clinical records and all deaths
without clear noncardiac cause were considered as cardiac
death.
• Myocardial infarction (MI): ST-segment elevation MI
(20 min lasting chest pain with 0.1 mV ST-segment
elevation in at least 2 contiguous leads) or non–ST-
segment elevation MI (typical chest pain with documen-
tation of transient 0.1 mV ST-segment depression or
T-wave modifications in at least 2 contiguous leads) with
any increase in serum cardiac enzymes above the 99th
percentile of the upper reference limit. Post-procedural
MI was defined as CK-MB increase 3 the upper
reference limit in patients with normal troponin T levels
before PCI and CK-MB increase 5 the pre-PCI
CK-MB levels in patients with abnormal troponin T
levels before PCI.
Target vessel revascularization: repeat PCI or coronary
surgery on the target vessel owing to recurrent ischemia.
Major adverse coronary events (MACE): death or MI or
target vessel revascularization.
Target bifurcation-related MACE: any MACE not
clearly caused by another vessel.
Target bifurcation angiographic failure: 50% reste-
nosis on the main vessel or TIMI flow grade 3 on the
SB at angiography performed during the follow-up.
Stent thrombosis was defined according to the Academic
Research Consortium criteria (8) as follows: “definite” 
angiography- or autopsy-confirmed stent thrombosis;
“probable”  any unexplained death within first 30 days
or any MI in the territory of the stent and in the absence Sof any other obvious cause; “possible”  any unexplained
death after 30 days.
Angiographic analyses. Pre-PCI, post-PCI, and follow-up
ngiography have been performed with the aim of allowing
-dimensional reconstruction and quantitative coronary
nalysis (3DQCA). Accordingly, at least 2 views have been
btained at least 30° apart. In cases of suboptimal imaging,
third obtained view was used to improve the 3D recon-
truction accuracy.
Offline 3DQCA analysis using the previously validated
ardiOp-B system (9–11) was performed by a trained
nterventional cardiologist (D.T.) who was blinded to clin-
cal and procedural characteristics, patients’ statuses, and
utcomes.
Using the 3DQCA reconstruction, the following parame-
ers have been obtained for pre- and post-PCI angiography:
Reference diameter of the MV
Minimal lumen diameter (MLD) and area (MLA) of
the MV
Percentage area stenosis of the MV
Reference diameter of the SB
MLD and MLA of the SB
Percentage area stenosis of the SB
MLD and MLA of the SB ostium (using the software’s
scroll bar tool)
Bifurcation proximal angle (angle between proximal MV
and SB)
Bifurcation distal angle (angle between SB and distal MV)
Study end points and sample size estimation. The study was
rimarily aimed at assessing the procedural characteristics
nd the acute angiographic results of patients with bifur-
ated lesions treated by the 2 types of DES.
The primary procedural and angiographic end points
ere respectively:
“SB trouble” (at least 1 or a composite of more than 1 of
the following procedural parameters: 1) SB TIMI flow
grade 3 after MV stenting; 2) need of guidewire(s)
different from the workhorse wire to rewire SB after MV
stenting; 3) failure to rewire the SB after MV stenting; or
4) failure to dilate the SB after MV stenting and SB
rewiring);
“SB acute angiographic result” (comparison of the 3DQCA-
estimated MLD in the SB ostium).
Such primary end points have been ideated and defined
or the first time in the present study. Accordingly, no
ublished data in the literature were available for any of the
tudy end points, thus limiting the strength of sample size
alculations. We hypothesized that the design of the EES
latform, because of higher possibility to dilate the side cells
nd owing to smaller strut width compared with that of
ES, could facilitate the provisional approach by reducing
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331the SB trouble and improving the angiographic result in the
SB. Accordingly, double sample sizing was performed as
follows. First, we observed that in the NORDIC I trial (12),
in the provisional arm using the SES, an MLD of 1.5 0.6
mm was observed after the procedure in the SB. Thus, we
calculated that, hypothesizing that EES was associated with
a 20% increase in the SB MLD, at least 64 patients for each
arm should be enrolled in the study to have an alpha error
of 0.05 and power of 0.8. Second, in a retrospective analysis
of 30 cases of bifurcated lesions treated by SES at our
institution, 7 patients (23.3%) were found to have SB
trouble, thus we calculated that at least 69 patients for each
arm should be enrolled to show a 50% reduction of SB
trouble with use of EES, with an alpha error of 0.05 and
power of 0.8. Finally, to compensate for any possible failure
or dropout, we decided to enroll 75 patients for each arm.
The following angiographic and clinical end points were
pre-defined secondary study end points:
• 3DQCA-estimated MLA in the SB ostium;
• “Target bifurcation failure” (TBF): defined as target
bifurcation-related MACE or target bifurcation angio-
graphic failure in the absence of MACE.
Statistical analysis. All analyses were performed according
to the intention to treat. Continuous variables were tested
for normality and for homogeneity of variance by
Kolmogorov-Smirnov and Levene tests, respectively, and
compared by unpaired Student t or Mann-Whitney U tests
s appropriate. Chi-square tests (Fisher corrected when
ppropriate) were used to compare discrete variables (re-
orted as raw numbers [%]). The incidence of TBF over
ime was studied using the Kaplan-Meier method and
ompared with log-rank tests.
Analyses were carried out using SPSS for Windows,
ersion 11.0 (SPSS Inc., Chicago, Illinois). Statistical sig-
ificance was defined by 2-tailed p  0.05.
esults
Study population characteristics and procedural outcome.
A total of 150 patients entered the study so that 75 patients
were randomly assigned to the SES group and 75 to the
EES group. The pre-intervention clinical and angiographic
characteristics are reported in the Table 1. Briefly, 28% of
the patients were diabetics; 37% presented with an acute
coronary syndrome; and 82% had normal ejection fraction.
The baseline characteristics were well balanced except for
the smoking status, which was significantly different be-
tween the 2 study groups.
Regarding the pre-PCI angiographic features, the target
bifurcation was located in an unprotected left main in 17% of
patients, and in the left anterior descending/diagonal branch
bifurcation in 62%; 30% of the bifurcated lesions were classifiedas Medina 1,1,1 and 43% had significant involvement of the
SB ostium. As shown in Table 1, all the baseline clinical and
angiographic characteristics were well balanced between the 2
study groups.
Table 1. Pre-PCI Clinical and Angiographic Characteristics of Patients
Randomized to SES or EES
SES
(n  75)
EES
(n  75) p Value
Age, yrs 65 9 64 10 0.86
Male 56 (75%) 64 (85%) 0.10
Risk factors
Family history of ischemic heart
disease
25 (33%) 23 (31%) 0.73
Diabetes mellitus 25 (33%) 19 (25%) 0.28
Hypertension 52 (69%) 52 (69%) 1.00
Hypercholesterolemia 40 (53%) 47 (63%) 0.25
Active smoking 9 (12%) 19 (25%) 0.036
Clinical history
Acute coronary syndrome at
presentation
29 (39%) 37 (49%) 0.19
Previous myocardial infarction 10 (13%) 6 (8%) 0.29
Previous coronary surgery 4 (5%) 5 (7%) 0.73
Extent of coronary artery disease
Single-vessel disease 32 (43%) 38 (51%) 0.33
2-vessel disease 20 (27%) 22 (29%) 0.72
3-vessel disease 23 (31%) 15 (20%) 0.13
Left main disease 10 (13%) 11 (15%) 0.81
Left ventricular function
Ejection fraction 50% 52 (69%) 54 (72%) 0.72
Ejection fraction 50% 23 (31%) 21 (28%)
Target bifurcation
Distal left main 11 (15%) 15 (20%) 0.39
Left anterior descending—diagonal 48 (64%) 45 (60%) 0.62
Left circumﬂex-marginal 10 (13%) 13 (17%) 0.50
Right posterior descending—
posterior lateral
6 (8%) 2 (3%) 0.15
ACC/AHA modiﬁed lesion classiﬁcation
Type B2 42 (56%) 43 (57%) 0.87
Type C 33 (44%) 32 (43%)
Plaque distribution on the
target bifurcation
Proximal main vessel 51 (68%) 47 (63%) 0.50
Distal main vessel 62 (83%) 64 (85%) 0.66
Side branch ostium 30 (40%) 30 (40%) 1.00
Medina bifurcation classiﬁcation
1.1.1 18 (24%) 19 (25%) 0.87
1.1.0 20 (27%) 17 (23%)
1.0.1 4 (5%) 2 (3%)
0.1.1 8 (11%) 9 (12%)
1.0.0 9 (12%) 9 (12%)
0.1.0 16 (21%) 19 (25%)
0.0.1 0 0
Values are mean SD or n (%).
ACC/AHA American College of Cardiology/American Heart Association; EES  everolimus-eluting stent(s); PCI percutaneous coronary intervention; SES sirolimus-eluting stent(s).
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332Procedural outcome and 3-dimensional quantitative angiography
results. Procedures were performed through radial access in
ost of the patients using 6-F guiding catheters (7- or 8-F
uiding catheters were used only in 16% of patients) and
lycoprotein IIb/IIIa inhibitors were administered in 16
atients (13% of EES vs. 8% of SES, p 0.29). All patients
eceived the SES or the EES according to randomization.
he details of procedural characteristics are reported in
able 2. Direct stenting on the MV was successfully
erformed in 36% of the cases. Kissing balloon inflation was
erformed in 67% of the patients after MV stenting and was
epeated at the end of procedure in all the 12 patients
eceiving a stent in the SB. All the main steps of provisional
rocedure were not significantly different between the
DES arms except for a smaller size of MV stent and
igher rate of MV post-dilation in the SES group. These
ifferences probably reflected the fact that a 4.0-mm stent
iameter is not available for SES so that a 3.5-mm SES
ollowed by post-dilation was used to treat large MV.
rotocol deviations leading to adoption of techniques dif-
erent from provisional TAP stenting occurred in 4 cases
3%) and consisted of 4 cases (2 SES and 2 EES) of
imultaneous kissing stenting motivated by the presence of
edina 0,1,1 lesions with similar size of MV and SB.
Optimal result (visual residual stenosis20%, TIMI flow
rade 3) was achieved in all patients in the MV, but in 6
4%) patients, the post-PCI SB flow was 3 (2 TIMI flow
rade 2 and 4 TIMI flow grade 0 to 1).
The procedural performance of EES and SES was not
ignificantly different as shown in Table 2. In particular, the
SB-trouble” end point occurred in 8 (11%) of EES patients
ompared with 12 (16%) of SES patients (p  0.34). The
umerically higher “SB-troubles” in SES, compared with
ES, were mainly driven by a double number (although
tatistically not significant) of procedures in which guide-
ires different from BMW were needed to rewire the SB
fter MV stenting (Table 2).
The 3DQCA results are reported in detail in Table 3.
aseline angiographic characteristics were similar be-
ween patients treated by EES or SES (Table 3). As
hown in Table 3, at post-PCI analysis, although MV
esults were similar, the lumen measures on the SB were
ignificantly higher in the EES group than in the SES
roup (ostium SB MLD: 1.94  0.72 mm in EES vs.
.64  0.62 mm in SES, p  0.013; ostium SB MLA:
.32  2.34 mm2 in EES vs. 2.37  1.50 mm2 in SES,
p  0.005).
Clinical outcome and angiographic follow-up data. The 18-
onth clinical follow-up rate was 100%. Overall, 10 pa-
ients had MACE during the follow-up: 2 cardiac deaths, 4
eriprocedural non–ST-segment elevation MI (2 in patients
ith subsequent cardiac death, 1 in patient with subsequent
e-PCI owing to in-stent restenosis), 4 non–ST-segment
levation MI (with documentation of in-stent restenosis Shat was treated by re-PCI), 10 repeated revascularizations
wing to symptomatic restenosis of the target bifurcation (7
e-PCI, 3 coronary artery bypass graft, 1 in patient with
eriprocedural MI, and 2 in patients with MI during
ollow-up). No definite or probable stent thrombosis was
bserved, and the 2 deaths have been also classified as
ossible stent thrombosis according to the Academic Re-
earch Consortium criteria. A detailed report of MACE is
n Table 4 and shows no difference between the EES and
Table 2. Procedural Characteristics in the Bifurcation PCI of Patients
Randomized to SES or EES
SES (n  75) EES (n  75) p Value
Vascular access
Radial 62 (83%) 53 (72%) 0.08
Femoral 13 (17%) 22 (28%)
Technical characteristics
Stent implanted according to
randomization
75 (100) 75 (100) 1.00
MV direct stenting 28 (37%) 23 (31%) 0.39
“SB trouble” 12 (16%) 8 (11%) 0.34
SB TIMI ﬂow grade 3 after MV
stenting
7 (9%) 8 (11%) 0.79
Need of guidewire(s) different from
the workhorse wire to rewire
SB after MV stenting
6 (8%) 3 (4%) 0.30
Failure to rewire the SB after
MV stenting
2 (3%) 3 (4%) 0.65
Failure to dilate the SB after MV
stenting and SB rewiring
1 (1%) 1 (1%) 1.00
Kissing balloon inﬂation after
MV stent
50 (67%) 51 (68%) 0.86
SB stenting 6 (8%) 6 (8%) 1.00
Kissing balloon inﬂation after
SB stent
6 (8%) 6 (8%) 1.00
MV stent post-dilation 51 (68%) 38 (51%) 0.031
MV stent
Stent diameter 3.1 0.4 3.4 0.5 0.001
Total stent length 30.3 16.5 29.6 13.7 0.78
SB stent
Stent diameter 3.1 0.5 2.9 0.5 0.42
Total stent length 21.8 10.3 18.9 5.0 0.51
Procedural result
Post-PCI TIMI ﬂow grade 3 in the MV 75 (100%) 75 (100%) 1.00
Post-PCI TIMI ﬂow grade 3 in the SB 72 (96%) 72 (96%) 1.00
Procedural success (TIMI ﬂow
grade 3 in both MV and SB,
visual residual stenosis
20% in MV)
72 (96%) 72 (96%) 1.00
Resources consumption
Contrast media, ml, mean  SD 251 108 246 133 0.83
Procedural time, min, mean  SD 70 43 81 32 0.50
Fluoroscopy time, min, mean  SD 20 13 20 11 0.85
Values are n (%) or mean SD.
MV  main vessel, SB  side branch; TIMI  Thrombolysis In Myocardial Infarction; other
abbreviations as in Table 1.ES groups.
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333During the follow-up, 62 patients (41%, 33 EES, 28
SES) had angiographic follow-up during the study. Among
these, 11 patients had target bifurcation angiographic fail-
ure: 10 were treated by re-PCI or coronary artery bypass
graft (as previously described) and 1 (treated by a single SES
on left anterior descending/diagonal bifurcation) had doc-
umentation of collateralized occlusion of the SB in the
absence of significant restenosis in the MV and was treated
medically (Table 4).
As a consequence, TBF, the pre-defined study clinical
end point, occurred in 7 (9.0%) SES patients versus 8 (11%)
EES patients at 18 months. Figure 3 represents the rate of
TBF in the 2 study groups at 6, 9, 12, and 18 months,
showing that few late adverse events were observed during
the study with both stents.
Finally, the low (41%) rate of angiographic follow-up,
and the fact that angiographic follow-up was performed on
clinical ground, did not to allow a reliable estimation of late
Table 3. 3DQCA Results in Patients Randomized to SES or EES
SES (n  75) EES (n  75) p Value
3DQCA before PCI
MV reference diameter, mm 2.37 0.63 2.47 0.73 0.38
MV minimal lumen diameter, mm 1.08 0.42 1.20 0.41 0.11
MV minimal lumen area, mm2 0.94 0.79 1.22 1.04 0.08
MV percentage area stenosis 80.0 13.7 75.9 14.7 0.08
SB reference diameter, mm 2.08 0.61 2.27 0.74 0.11
SB minimal lumen diameter, mm 1.59 0.66 1.67 0.69 0.50
SB minimal lumen area, mm2 1.71 1.59 2.03 1.86 0.29
Minimal lumen diameter at
SB ostium, mm
1.72 0.52 1.84 0.73 0.26
Minimal lumen area at
SB ostium, mm2
2.63 1.65 3.02 2.53 0.29
SB percentage area stenosis 50.2 24.1 54.6 23.1 0.27
Bifurcation proximal angle, ° 133.8 19.0 132.9 20.2 0.78
Bifurcation distal angle, ° 65.0 18.7 67.0 17.7 0.51
3DQCA after PCI
MV reference diameter, mm 3.10 0.67 3.34 0.687 0.08
MV minimal lumen diameter, mm 2.62 0.51 2.76 0.57 0.14
MV minimal lumen area, mm2 5.22 2.21 5.83 2.89 0.16
MV percentage area stenosis 29.3 14.1 30.8 13.7 0.55
SB reference diameter, mm 1.92 0.48 2.25 0.70 0.002
SB minimal lumen diameter, mm 1.49 0.65 1.81 0.91 0.020
SB minimal lumen area, mm2 1.77 1.25 2.70 2.33 0.004
Minimal lumen diameter at
SB ostium, mm
1.64 0.62 1.94 0.72 0.013
Minimal lumen area at
SB ostium, mm2
2.37 1.50 3.32 2.34 0.005
SB percentage area stenosis 43.9 23.9 39.4 22.3 0.27
Bifurcation proximal angle, ° 133.6 16.3 134.6 17.9 0.76
Bifurcation distal angle, ° 58.5 14.4 61.6 16.9 0.25
Values are mean SD.
3DQCA  3-dimensional reconstruction and quantitative coronary analysis; other abbrevia-
tions as in Tables 1 and 2.loss for the 2 types of DES.Discussion
The present single-center trial comparing EES and SES in
unselected patients undergoing PCI on bifurcated lesions
using a provisional TAP-stenting approach shows that:
• SB management is not significantly affected by the use of
the (very different) SES or EES platforms;
• The 3-dimensional angiographic result is improved in
the SB ostium using EES, compared with using SES.
Bifurcated lesions constitute a challenging subset of coro-
nary lesions. Albeit not specifically designed for this, DES
may be implanted in bifurcated lesions using different
techniques resulting in improved outcomes compared with
bare-metal stents (1). Even if the optimal technique to treat
all bifurcated lesions has not still been identified, the simple
approach of implanting the DES in the MV (i.e., the
“provisional stenting approach”) is gradually emerging as the
gold standard for the majority of bifurcated lesions (2).
When the provisional approach with DES is adopted,
another important issue is DES selection. Indeed, available
DES exhibit profound differences of both platform and
drug-coating technology; thus, prospective randomized tri-
als in the specific field of bifurcated lesions are warranted.
Previous studies comparing first-generation DES in pa-
tients with bifurcated lesions showed some potential angio-
graphic and clinical advantages for SES over the paclitaxel-
eluting stent (3,4). These data support the notion that in
bifurcated lesions different DES may be associated with
different outcomes, confirming the need of head-to-head
comparisons in this field.
In this study, we compare SES, a first-generation DES
with well-established efficacy, with an EES, a promising
last-generation DES, in the challenging field of bifurcation
PCI. We have focused our attention on the procedural and
angiographic performances of these stents. Indeed, EES
and SES probably represent 2 extremes of the possible
Table 4. Adverse Events and Angiographic Failures Observed During the
Follow-Up Patients Randomized to SES or EES
SES
(n  75)
EES
(n  75) p Value
Any major adverse cardiac event 7 (9%) 9 (12%) 0.60
Cardiac death 1 (1%) 1 (1%) 0.56
Periprocedural myocardial infarction* 1 (1%) 3 (4%) 0.31
Myocardial infarction after discharge* 1 (1%) 3 (4%) 0.31
Target vessel revascularization 5 (7%) 5 (7%) 1.00
Target bifurcation angiographic failure 6 (8%) 5 (7%) 0.75
Associated to major adverse coronary events 5 (7%) 5 (7%) 1.00
Detected by angiography and not treated nor
associated to major adverse coronary events
1 (1%) 0 (0%) 0.32
Target bifurcation failure 7 (9%) 8 (11%) 0.78
*All myocardial infarctions were non–ST-segment elevation.Abbreviations as in Table 1.
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334evolution of stent technology regarding their adaptability to
bifurcated lesions. On 1 hand, the SES platform is charac-
terized by thick (0.0055-inch) stainless steel struts and by a
cell design that has been associated with limited side-cell
expansion (13). By contrast, the EES stent platform is based
on a thin (0.0032-inch) cobalt chromium strut structure
with a cell design that allows obtainment of larger side cells
after SB balloon dilation (14). To assess the EES and SES
procedural performance, we prospectively collected a de-
tailed series of pre-defined procedural parameters (which
should provide a detailed report of the bifurcation PCI
complexity) and analyzed the acute angiographic outcome
using a dedicated 3DQCA software. This approach should
provide useful information to assess whether differences of
DES design (previously well described in bench testing)
may translate in different procedural outcomes. Although,
some recent observations from substudies of larger trials not
focused on bifurcated lesions have suggested that the an-
giographic outcome of small SBs may be influenced by the
stent platform favoring last-generation DES designs com-
pared with the first-generation paclitaxel-eluting stent
(15,16), no published study has systematically and prospec-
tively assessed the SB procedural and angiographic outcome
on unselected bifurcated lesions (in which jailed wire pro-
tection, SB rewiring, kissing balloon dilation, and SB
stenting were eventually performed). Theoretically, as the
stent platform of EES is characterized by side cells, which
may be deformed by SB ballooning up to larger diameters,
it should both facilitate the performance of provisional
stenting and provide better angiographic results in the SB
Figure 3. Survival Free From TBF
Patients free from target bifurcation failure (TBF) during the study accord-
ing to randomization (SES or EES). Abbreviations as in Figure 1.than if an SES were used. Overall, the observed results seemto provide 2 different insights. Indeed, although the EES
was associated with better angiographic results in the SB as
evaluated by 3DQCA, it failed to facilitate the management
of bifurcation when compared with SES use. This latter
finding may have different explanations. First, the “SB
trouble” may have not been adequately powered as the
expected rate in SES group was 23.3% versus 16% observed
in the study and the expected risk ratio was 50% versus 30%
observed in the study. Second, the ideal stent characteristics
for SB rewiring and ballooning are still unclear: both
side-cell shape and area may be equally relevant for MV
side-cell recrossing so that a more favorable shape may
theoretically compensate for lower cell area. As a conse-
quence, it is possible that the SES platform characteristics,
although being theoretically somewhat inferior to EES, are
sufficient to successfully manage most unselected bifurcated
lesions.
Finally, the initial advantage associated with EES with
regard to the angiographic measures of SB ostium did not
translate into reduction of TBF when compared with SES
use, thus reinforcing the perception of an overall limited
clinical relevance for SB angiographic result during bifur-
cation PCI (17). The study, however, was by far underpow-
ered to show differences in the clinical outcome so the
described clinical findings should be regarded as explorative.
In this view, it should be noted that, in the treatment of
unselected bifurcated lesions, a systematic provisional-TAP
approach with low rate of SB stenting is associated to low
rates of major adverse events and clinically evident resteno-
sis, so that very large numbers of patients are required to
detect differences between various DES.
Study limitations. The results of the present study are based
on a small study population so that reliable subgroup
analyses according to the type and location of the target
bifurcation has not been possible. Moreover, as no system-
atic angiographic follow-up has been planned in the study
protocol, the low rate of angiographic follow-up obtained
did not allow reliable comparison of late angiographic
outcome measures.
Conclusions
The results of the present prospective study suggest that, in
patients with coronary bifurcated lesions treated by provi-
sional technique, EES, compared with SES, is associated
with similar procedural performance and better 3DQCA
results in the SB. Both stents are associated with low rates
of major adverse events and angiographic failure.
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